As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.

As demand for GLP‑1 therapies grows in obesity and Type 2 diabetes care, manufacturers must rapidly scale production while meeting strict GMP requirements. This case study shows how Boccard delivered a robust and scalable GLP‑1 production line.